Award disclosed
Eric H. L. So
Director
Common Shares
- Value context
- Unavailable
- Reported price
- Price not reported
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Helus Pharma Inc.
Last 30 daysInsiders bought $8.42M · 4 buyers, led by Eric H. L. So (Executive Chair) with $3.57M. No qualifying insider sales.
Director
Common Shares
Chief Growth Officer
Common Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common SharesGrant or award | 248,000Price not reported | Unavailable | Sep 30Filed Oct 1 · 1d later | SEC filing |
| Chief Growth Officer | Common SharesGrant or award | 248,000Price not reported | Unavailable | Sep 30Filed Oct 1 · 1d later | SEC filing |
$6,901,848 of common-equity purchase value after transaction-age decay across 180 days.
4 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
4 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.